AA
CORT icon

AlphaMark Advisors’s Corcept Therapeutics CORT Stock Holding History

AlphaMark Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$21K Sell
411
-9,328
-96% -$489K 0.01% 346
2024
Q3 		$451K Buy
9,739
+9,328
+2,270% +$331K 0.16% 84
2024
Q2 		$13K Sell
411
-8,964
-96% -$246K ﹤0.01% 492
2024
Q1 		$236K Buy
+9,375
New +$221K 0.08% 215

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AlphaMark Advisors's CORT Position: Q4 2024 in Review

AlphaMark Advisors reduced its Corcept Therapeutics (CORT) stake by 96% in Q4 2024, selling an estimated $489K and leaving 411 shares worth $21K. The position accounts for 0.01% of the portfolio, ranked #346.

AlphaMark Advisors first reported a position in CORT in Q1 2024 and has held it in 4 quarters since. The position peaked at $451K in Q3 2024. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • AlphaMark Advisors held 411 shares of Corcept Therapeutics worth $21K as of Q4 2024.
  • AlphaMark Advisors sold 9,328 Corcept Therapeutics shares in Q4 2024, an estimated $489K.
  • Corcept Therapeutics made up 0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #346 holding.
  • AlphaMark Advisors first reported a position in Corcept Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • AlphaMark Advisors's Corcept Therapeutics position peaked at $451K in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.